BioCryst ready to take on HCV players with $101m Presidio acquisition
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals will use its late-stage influenza and gout drug candidates to finance Phase I and II clinical trials in hepatitis C virus (HCV) and hereditary angioedema (HAE) as it acquires HCV-focused Presidio Pharmaceuticals for $101 million in BioCryst stock.